MYL9 and melanoma: MLC-2 is upregulated in different cancer types, including melanoma [48], hepatocellular carcinoma [25], oesophageal squamous cell carcinoma [49], and PDAC [50], making it an important prognosis and therapeutic target in cancer biomechanics [51].